Before Christophe Echeverri decided to spin his postdoctoral project into a biotech company called Cenix BioScience in 1999, he hesitated, fearing the switch from lab coat to business suit was a "move over to the dark side." Echeverri had been invited to turn the research he was doing at the European Molecular Biology Laboratory in Heidelberg into a commercial venture under the well-endowed wing of the Max Planck Institute, Germany's elite scientific research body. Echeverri didn't hesitate long, seeing the opportunity as a once-in-a-lifetime chance to prove that his theories actually worked. So when the new Max Planck Institute of Molecular...
Economic Recovery: Labs Get Down to Business
BIOTECHNOLOGY: CENIX
Subscriber content preview.
or
Log-In
To continue reading:
or
Log-In